Medical organizations and international experts have renamed Polycystic Ovary Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS) this month [1].
The change aims to correct a long-standing misconception that the disorder is solely a gynecological condition. By emphasizing the endocrine and metabolic components, health officials intend to improve the accuracy of diagnoses and the quality of patient care.
The announcement occurred in May 2026 [2]. The new terminology, Polyendocrine Metabolic Ovarian Syndrome, explicitly identifies the multisystem nature of the disease. Experts said the previous name focused too heavily on the ovaries, which may have led clinicians to overlook the broader systemic effects on a patient's health.
According to medical reports, the condition impacts the endocrine system, metabolic functions, and the ovaries. The shift in nomenclature is intended to encourage a more holistic approach to treatment, one that addresses insulin resistance and hormonal imbalances alongside reproductive health.
Advocates for female health said the update helps move the conversation away from a narrow focus on cysts. This transition reflects a growing understanding of how the syndrome affects the entire body rather than a single organ system.
“The condition formerly known as Polycystic Ovary Syndrome (PCOS) has been renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS).”
The transition from PCOS to PMOS represents a shift in clinical perspective from a localized reproductive issue to a complex metabolic disorder. By integrating 'endocrine' and 'metabolic' into the official name, the medical community is signaling that treatment must prioritize systemic health—such as blood sugar regulation and hormonal stability—rather than focusing primarily on ovarian morphology.
